Cougar Biotechnology has started enrolling patients in its Phase III clinical trial of the company's lead drug candidate CB7630.

Cougar Biotechnology has reported positive data from the Phase I dose ranging trial of company's prostate cancer drug candidate CB7630 or abiraterone acetate.

Cougar Biotechnology has been enrolled in an open label, dose escalating Phase I trial of the company's drug candidate noscapine, an orally active inhibitor of microtubule dynamics.

Cougar Biotechnology has announced positive findings from Phase I data on the company's prostate cancer drug candidate.